OncoSec Medical Inc (ONCSQ)

[Titan V]

Also we shouldn’t forget ONCS has Orphan Drug Designation. If approved (AA) in 2019, they will have market exclusivity for 7 years for intratumoral electroporation of IL-12. So even if their patents expire in 2022, they will have protection until 2026. By that time the multi gene pipeline will have matured to a good extent as well. I see no reason to be concerned here. I also doubt these facts were not considered by Steve Cohen before he decided to invest.